SRR13780269
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.420
- PANCREAS_BETA_CELLS+0.390
- MYC_TARGETS_V1+0.290
- DNA_REPAIR+0.270
- MITOTIC_SPINDLE+0.260
- SPERMATOGENESIS+0.090
- MYC_TARGETS_V2+0.070
- HEDGEHOG_SIGNALING+0.030
- MTORC1_SIGNALING+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.640
- INTERFERON_GAMMA_RESPONSE-0.590
- IL6_JAK_STAT3_SIGNALING-0.560
- ALLOGRAFT_REJECTION-0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INFLAMMATORY_RESPONSE-0.470
- TNFA_SIGNALING_VIA_NFKB-0.460
- COAGULATION-0.450
- ANGIOGENESIS-0.400
- APOPTOSIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13780268 | — | cohortSC | 0.962 |
| 2 | BS_EFE4YEK3 | medulloblastoma | — | 0.959 |
| 3 | BS_Y8D1F5WW | medulloblastoma | — | 0.953 |
| 4 | BS_FCAKKZ20 | medulloblastoma | — | 0.951 |
| 5 | BS_HD4EJYE3 | medulloblastoma | — | 0.945 |
| 6 | BS_BSV07M7Z | medulloblastoma | — | 0.944 |
| 7 | BS_WH5HDE0A | medulloblastoma | — | 0.944 |
| 8 | BS_G00FHF3Q | medulloblastoma | — | 0.943 |
| 9 | BS_4PH1MBGR | medulloblastoma | — | 0.943 |
| 10 | BS_ERWT0ZWE | medulloblastoma | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |